Rapport Therapeutics (RAPP) Competitors $25.78 +0.90 (+3.62%) Closing price 04:00 PM EasternExtended Trading$25.83 +0.05 (+0.19%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENSShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Rapport Therapeutics (NASDAQ:RAPP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Is RAPP or KYMR more profitable? Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Rapport Therapeutics' return on equity of -29.99% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A -29.99% -28.64% Kymera Therapeutics -616.03%-31.60%-27.12% Do analysts recommend RAPP or KYMR? Rapport Therapeutics currently has a consensus price target of $35.33, suggesting a potential upside of 37.06%. Kymera Therapeutics has a consensus price target of $61.26, suggesting a potential downside of 2.59%. Given Rapport Therapeutics' higher possible upside, equities analysts clearly believe Rapport Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 Which has preferable valuation & earnings, RAPP or KYMR? Rapport Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$78.31M-$2.50-10.31Kymera Therapeutics$47.07M95.53-$223.86M-$3.47-18.12 Which has more risk & volatility, RAPP or KYMR? Rapport Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Does the media prefer RAPP or KYMR? In the previous week, Kymera Therapeutics had 4 more articles in the media than Rapport Therapeutics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 6 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.76 beat Kymera Therapeutics' score of 0.27 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRapport Therapeutics and Kymera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$940.97M$3.40B$6.04B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-10.3122.9285.4427.36Price / SalesN/A268.92515.69196.40Price / CashN/A46.9537.5761.53Price / Book3.0910.5512.426.82Net Income-$78.31M-$52.58M$3.32B$276.89M7 Day Performance-4.73%1.09%1.01%0.27%1 Month Performance4.25%16.09%10.75%8.31%1 Year Performance-0.39%18.41%76.20%35.60% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics2.7916 of 5 stars$25.78+3.6%$35.33+37.1%+2.0%$940.97MN/A-10.31N/AKYMRKymera Therapeutics1.3516 of 5 stars$57.55-0.6%$61.26+6.5%+26.5%$4.14B$47.07M-16.58170Insider TradePTGXProtagonist Therapeutics1.6812 of 5 stars$64.14-1.1%$68.36+6.6%+66.0%$4.03B$209.18M91.63120Positive NewsAnalyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals3.7504 of 5 stars$41.68+2.0%$74.45+78.6%-17.0%$3.93B$1.39M-10.14210ZLABZai Lab2.7796 of 5 stars$33.31-1.3%$56.35+69.2%+18.9%$3.77B$398.99M-16.331,869News CoveragePositive NewsAKROAkero Therapeutics3.6818 of 5 stars$46.04-0.1%$81.14+76.2%+79.3%$3.69BN/A-23.0230Insider TradeACADACADIA Pharmaceuticals4.5081 of 5 stars$21.59-1.0%$29.12+34.9%+35.8%$3.68B$1.02B16.23510Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600News CoverageGap UpMIRMMirum Pharmaceuticals3.0855 of 5 stars$72.53-0.6%$76.50+5.5%+84.3%$3.66B$336.89M-59.94140Positive NewsLNTHLantheus4.5632 of 5 stars$52.70-2.1%$85.50+62.2%-50.3%$3.66B$1.53B14.02700Trending NewsAnalyst RevisionMENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031 Related Companies and Tools Related Companies KYMR Competitors PTGX Competitors CRNX Competitors ZLAB Competitors AKRO Competitors ACAD Competitors AAPG Competitors MIRM Competitors LNTH Competitors MENS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
